Loading clinical trials...
Loading clinical trials...
AOC 1001-CS1 is a randomized, double-blind, placebo-controlled, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple-doses of AOC 1001 Adm...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Avidity Biosciences, Inc.
NCT07486934 · Myotonic Dystrophy Type 1 (DM1), DM1, and more
NCT06809049 · Myotonic Dystrophy, Congenital, Myotonic Dystrophy, Type 1 (DM1), and more
NCT06300307 · Myotonic Dystrophy 1
NCT06523400 · Myotonic Dystrophy
NCT05854433 · Myotonic Dystrophy Type 2, Myotonic Dystrophy Type 1
University of California Los Angeles
Los Angeles, California
Stanford University
Palo Alto, California
University of Colorado
Denver, Colorado
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions